What is BrainQ?
Founded in 2011, BrainQ operates at the vanguard of neuro-technology, specializing in the development of a breakthrough platform for precision neurology. The company utilizes a sophisticated BCI-based approach to treat the impaired brain, aiming to restore function and improve patient outcomes through data-driven, personalized therapeutic interventions. Headquartered in Israel, BrainQ integrates deep clinical research with cutting-edge engineering to address the unmet needs of patients suffering from neurological conditions. Its market position is defined by its ability to bridge the gap between complex neural data and actionable, non-invasive treatment protocols, establishing it as a key player in the global digital health landscape.
How much funding has BrainQ raised?
BrainQ has raised a total of $48.8M across 2 funding rounds:
Unspecified
$8.8M
Unspecified
$40M
Unspecified (2018): $8.8M with participation from Norma Investments, IT-Farm, OurCrowd.com, Qure Ventures, and Amir Gross
Unspecified (2021): $40M led by Peregrine Ventures, Dexcel Pharma Technologies, and Hanaco
Key Investors in BrainQ
Peregrine Ventures
Peregrine Ventures is a specialized life science investment firm that supports medical innovation through strategic capital and deep industry expertise, focusing on companies at various stages of development.
Hanaco
Hanaco Ventures is a venture capital firm with a dual presence in Israel and the United States, dedicated to nurturing high-potential startups and supporting founders through decisive, collaborative investment strategies.
IT-Farm
IT-Farm acts as a general partner for specialized investment funds, providing professional business consulting and strategic guidance to foster growth in the technology and healthcare sectors.
What's next for BrainQ?
With the infusion of $40M, BrainQ is poised to transition from clinical validation to broader commercial implementation. The strategic roadmap likely includes the expansion of its clinical trial infrastructure and the refinement of its BCI algorithms to support a wider array of neurological indications. As the company scales, it will focus on navigating regulatory pathways and fostering partnerships with healthcare providers to integrate its technology into standard clinical workflows. The focus remains on achieving long-term sustainability while maintaining the rigorous scientific standards required for medical device approval in international markets.
See full BrainQ company page
